anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
As the price of bitcoin rose to $44,000 in December 2023, Bukele announced that El Salvador's investment into bitcoin had broken even. In March 2024, he stated that El Salvador had made a 50-percent profit from bitcoin. Bukele mocked news-media outlets on Twitter, saying that there were "literally thousands of articles" about El Salvador's bitcoin losses and the same outlets were now "totally silent". By 19 January 2025, the Salvadoran government had 6,043 bitcoins worth $611.2 million. In November 2021, Bukele announced that he planned to build Bitcoin City in the southeastern region of La Unión at the base of the Conchagua volcano. The city would use geothermal energy to power bitcoin mining. Ricardo Navarro, head of the Salvadoran Center of Appropriate Technology, criticized the plan, adding that it would result in an "environmental disaster". Bukele published images of models of Bitcoin City and its planned airport on Twitter in May 2022, saying that the city would have "no income tax, zero property tax, no procurement tax, zero city tax, and zero CO2 emissions". In December 2023, the Legislative Assembly passed a law that allowed individuals to purchase Salvadoran citizenship by donating bitcoins to El Salvador. On 18 December 2024, the International Monetary Fund (IMF) agreed to give El Salvador a $1.4 billion loan in exchange for the Salvadoran government making some concessions from the Bitcoin Law.
Army Apache helicopter crashes near the Strait of Hormuz. The crew is rescued safely. Trump attends Game 3 of the NBA Finals, becoming the first sitting president to do so. Trump nominates Todd Blanche to serve as the U.S. attorney general, where he currently serves in an acting capacity. The U.S. House Committee on Oversight and Government Reform releases a report accusing Minnesota Governor Tim Walz and Minnesota Attorney General Keith Ellison of being aware of widespread fraud in federally-funded social programs. Vance refers both officials to the Department of Justice for criminal fraud investigation. June 9 Controversial candidate Graham Platner wins the Democratic primary for the US Senate election in Maine. Iran war: The U.S. military launches new strikes against Iran in response to the downing of a U.S. Army Apache helicopter near the Strait of Hormuz, further straining a fragile ceasefire. June 10 Trump quips "I love inflation" despite inflation reaching a three-year high of 4.2%, up from 3.8% a month earlier, driven by rising energy costs. Trump signs legislation providing nearly $70 billion to fund ICE and the Border Patrol through the remainder of his term, ending a nearly six-month dispute over Department of Homeland Security funding. 2026 NBA Finals: In basketball, the New York Knicks rally from a 29-point deficit to beat the San Antonio Spurs 107–106 in Game 4, taking a 3–1 series lead in the NBA Finals after OG Anunoby tipped in the game-winning basket with 1.2 seconds remaining.
In 1930, Fred Allison of the Alabama Polytechnic Institute claimed to have discovered element 87 (in addition to 85) when analyzing pollucite and lepidolite using his magneto-optical machine. Allison requested that it be named virginium after his home state of Virginia, along with the symbols Vi and Vm. In 1934, H.G. MacPherson of UC Berkeley disproved the effectiveness of Allison's device and the validity of his discovery. In 1936, Romanian physicist Horia Hulubei and his French colleague Yvette Cauchois also analyzed pollucite, this time using their high-resolution X-ray apparatus. They observed several weak emission lines, which they presumed to be those of element 87. Hulubei and Cauchois reported their discovery and proposed the name moldavium, along with the symbol Ml, after Moldavia, the Romanian province where Hulubei was born. In 1937, Hulubei's work was criticized by American physicist F. H. Hirsh Jr., who rejected Hulubei's research methods. Hirsh was certain that eka-caesium would not be found in nature, and that Hulubei had instead observed mercury or bismuth X-ray lines. Hulubei insisted that his X-ray apparatus and methods were too accurate to make such a mistake. Because of this, Jean Baptiste Perrin, Nobel Prize winner and Hulubei's mentor, endorsed moldavium as the true eka-caesium over Marguerite Perey's recently discovered francium. Perey took pains to be accurate and detailed in her criticism of Hulubei's work, and finally she was credited as the sole discoverer of element 87.
Sources: en.wikipedia.org
== See also == Bond number – Dimensionless number in fluid dynamicsPages displaying short descriptions of redirect targets Bound water – Thin layer of water surrounding mineral surfaces Capillary action through synthetic mesh Capillary fringe – Subsurface layer in which groundwater seeps up from a water table by capillary action Capillary pressure – Pressure between two fluids from forces between the fluids and tube walls Capillary wave – Wave on the surface of a fluid, dominated by surface tension Capillary bridges – Minimised surface of liquid connecting two wetted objectsPages displaying short descriptions of redirect targets Damp proofing – Type of moisture control in building construction Darcy's law – Equation describing the flow of a fluid through a porous medium Frost flower – Thin layer of ice extruded from a plant Frost heaving – Upwards swelling of soil during freezing Hindu milk miracle – 1995 alleged miracle incidentsPages displaying short descriptions of redirect targets Krogh model Porosimetry – Measurement and characterization of the porosity of a material Needle ice – Ice column formed when liquid groundwater rises into freezing air Surface tension – Tendency of a liquid surface to shrink to reduce surface area Washburn's equation – Equation describing the penetration length of a liquid into a capillary tube with time Young–Laplace equation – Describing pressure difference over an interface in fluid mechanics
The RFamide peptide family, or the RFamide-related peptides (RFRPs), are a family of neuropeptides. They are characterized by the possession of an Arg-Phe-NH2 motif at their C-terminal extremities. Members of the family include:
==== Fiction that references Jung's theories ==== Hermann Hesse, author of works such as Siddhartha and Steppenwolf, was treated by Joseph Lang, a student of Jung. For Hesse this began a long preoccupation with psychoanalysis, through which he came to know Jung personally. The Canadian novelist Robertson Davies made Jungian analysis a central part of his 1970 novel The Manticore. He stated in a letter, "There have been other books which describe Freudian analyses, but I know of no other that describes a Jungian analysis" adding "I was deeply afraid that I would put my foot in it, for I have never undergone one of those barnacle-scraping experiences, and knew of it only through reading. So, I was greatly pleased when some of my Jungian friends in Zurich liked it very much." The psychological novel E.E. written by Olga Tokarczuk draws from Jung's doctoral dissertation On the Psychology and Pathology of So-Called Occult Phenomena. Jung is not a character in this story, but Jung's views on the occult are extensively cited.
Sources: en.wikipedia.org
An insulin pump allows the replacement of slow-acting insulin for basal needs with a continuous infusion of rapid-acting insulin. The insulin pump delivers a single type of rapid-acting insulin in two ways:
As much as 90% of testosterone is converted into 5α-DHT in so-called androgenic tissues with high 5α-reductase expression, and due to the several-fold greater potency of 5α-DHT as an AR agonist relative to testosterone, it has been estimated that the effects of testosterone are potentiated 2- to 3-fold in such tissues.
== History == Sildenafil (compound UK-92,480) was synthesized in 1989 by a group of pharmaceutical chemists led by Simon Campbell working at Pfizer's Sandwich, Kent, research facility in England. It was initially studied for use in hypertension (high blood pressure) and angina pectoris (a symptom of ischaemic heart disease). The first clinical trials were conducted in Morriston Hospital in Swansea. Phase I clinical trials under the direction of Ian Osterloh suggested the drug had little effect on angina, but it could induce marked penile erections. Pfizer therefore decided to market it for erectile dysfunction, rather than for angina; this decision became an often-cited example of drug repositioning. The drug was patented in 1996, approved for use in erectile dysfunction by the FDA on 27 March 1998, becoming the first oral treatment approved to treat erectile dysfunction in the United States, and offered for sale in the United States later that year. It soon became a great success: annual sales of Viagra peaked in 2008 at US$1.934 billion.
The widespread nature of Gulf of Mexico chemosynthetic communities was first documented during contracted investigations by the Geological and Environmental Research Group (GERG) of Texas A&M University for the Offshore Operators Committee. This survey remains the most widespread and comprehensive, although numerous additional communities have been documented since that time. Industry exploration for energy reserves in the Gulf of Mexico has also documented numerous new communities through a wide range of depths, including the deepest-known occurrence in the Central Gulf of Mexico in Alaminos Canyon Block 818 at a depth of 2,750 metres (9,020 feet). The occurrence of chemosynthetic organisms dependent on hydrocarbon seepage has been documented in water depths as shallow as 290 metres (950 feet) and as deep as 2,744 metres (9,003 feet). This depth range specifically places chemosynthetic communities in the deepwater region of the Gulf of Mexico, which is defined as water depths greater than 305 metres (1,001 feet). Chemosynthetic communities are not found on the continental shelf, although they do appear in the fossil record in water shallower than 200 metres (660 feet). One theory explaining this is that predation pressure has varied substantially over the time period involved (Callender and Powell 1999). More than 50 communities are now known to exist in 43 Outer Continental Shelf (OCS) blocks.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.